LY-213024

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLY-213024
Drug Alias NameLY-213024
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene B4 receptor antagonists
TargetsLeukotriene B4 receptor
Therapy Area/IndicationsInflammationHypersensitivityAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsInflammationHypersensitivityAsthma

Other Information

ATC CodeN/A
Related LinksN/A